BCAT1 for the Diagnosis and Prognosis of Brain Tumors
Glioblastomas are the most common and most aggressive human malignant brain tumors. Treatment options for glioblastomas and other gliomas include neurosurgical techniques (resection or stereotactic procedures), radiation therapy and chemotherapy.
Knowledge of the diagnostic and prognostic fac-tors is crucial for the selection of the best form of life-prolonging therapy. Studies have shown that glioma patients harboring an isocitrate dehydrogenase (IDH) 1 or 2 mutation have a better prognosis compared to glioma patients with wild-type IDH1 and IDH2. DKFZ researchers have demonstrated that gliomas with increased (>3 fold compared to control) branched-chain aminotransferase 1 (BCAT1) expression do not harbor IDH1 or IDH2 mutations and thus have a poor prognosis. The present invention allows a fast and reliable diagnostic and prognostic classification of tumors based on the activity of branched-chain amino acid metabolism as reflected by the level or activity of BCAT1.
Further Information: PDF
Deutsches Krebsforschungszentrum DKFZ
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Microscopic basis of a new form of quantum magnetism
Not all magnets are the same. When we think of magnetism, we often think of magnets that stick to a refrigerator’s door. For these types of magnets, the electronic interactions…
An epigenome editing toolkit to dissect the mechanisms of gene regulation
A study from the Hackett group at EMBL Rome led to the development of a powerful epigenetic editing technology, which unlocks the ability to precisely program chromatin modifications. Understanding how…
NASA selects UF mission to better track the Earth’s water and ice
NASA has selected a team of University of Florida aerospace engineers to pursue a groundbreaking $12 million mission aimed at improving the way we track changes in Earth’s structures, such…
